LabPON Achieves 100 Percent Digital Diagnosis for Clinical Cases with Philips

Philips Royal Philips (NYSE: PHG, AEX: PHIA) announced that the Netherlands-based LabPON has become the first clinical pathology laboratory in the world to have transitioned completely to digital diagnosis. With this shift, all clinical histology cases are now being assessed and diagnosed digitally with the Philips IntelliSite Pathology Solution instead of with a microscope, leading to improved laboratory efficiency, quality and service levels.

Pathology plays a critical role in disease detection, particularly with cancer diagnosis. Suspicious tissue samples are investigated through a microscope to determine if the tissue is malignant and consequently guides treatment decisions. As the largest pathology laboratory in the Netherlands, LabPON is consulted on more than 54,000 histological cases each year, which translates to more than 300,000 slides of human tissue. Each of these slides needs to be prepared, analyzed, diagnosed, reported and archived every year. Digitizing these images eases collaboration across sites, reducing costs. Improved cooperation also allows access to specialists, engendering multidisciplinary discussions to share expertise and knowledge to ultimately come to a better diagnosis for the patient.

"Transitioning our entire workflow to digital processes demonstrates our commitment to ensuring our patients and clinical colleagues receive the fastest, most effective and best informed diagnoses possible," said Alexi Baidoshvili, pathologist, LabPON. "The revolutionary pathology solution from Philips provides us the images and speed we need, and their IT product seamlessly integrates with existing lab systems, while improving collaboration. Philips' understanding of the needs of our pathologists has ensured their adoption and improved throughput."

"Digitization of pathology offers a new way to tackle some of the growing challenges in the field, like higher cancer rates and the massive quantity of slides generated annually at these sites," said Russell Granzow, General Manager, Philips Digital Pathology Solutions. "LabPON's success in moving to entirely digital workflows emphasizes the role our solutions are playing across the health continuum to enable definitive diagnosis and improved patient care."

LabPON, which has 17 pathologists and a total of 115 employees, is also partnering with two other major labs in the Netherlands - University Medical Center Groningen and Isala Klinieken in Zwolle - to form a virtual network that allows 49 pathologists to collaborate easily, share cases in a secured way, and directly set up consultations.

LabPON has been working toward this milestone with Philips since 2012, using a structured change management approach to full digital adoption by its pathologists. This makes LabPON and Philips a valuable resource seeking to help others in their digital transformation.

Philips is an innovator in health technologies to enhance patient care and cure from healthy living and prevention, to diagnosis, treatment and home care. The company is a pioneer and leader in digital pathology, with a fast growing installed base and innovation partnerships with leading healthcare providers across the globe.

Philips IntelliSite Pathology Solution is a new platform to help pathologists make that next step in workflow improvement and accelerate knowledge sharing between care providers. Digital pathology will open up new ways to get more information from tissue samples and connect with other diagnostic modalities. Philips IntelliSite Pathology Solution is CE marked for primary diagnostics in the EU and Health Canada. In the U.S., Philips IntelliSite Pathology Solution is cleared by FDA for diagnostic use in the evaluation of HER2 expression in breast cancer and is offered for research use (RUO).

Related news articles:

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people's lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2014 sales of EUR 21.4 billion and employs approximately 108,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare.

About LabPON
LabPON represents Laboratory Pathology East Netherlands and is located in in Hengelo, The Netherlands. LabPON carries out pathological examinations for hospitals and general practices in the region Twente and Achterhoek- East. As the largest pathology laboratory in the Netherlands, it is committed to excel in speed and quality to the benefit of each patient. The development of digital pathology will certainly contribute to this.

Most Popular Now

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

Alcidion Grows Top Talent in the UK, wit…

Alcidion has today announced the addition of three new appointments to their UK-based team, with one internal promotion and two external recruits. Dr Paul Deffley has been announced as the...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...

AI, Full Automation could Expand Artific…

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

MIT Researchers Use Generative AI to Des…

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). Using generative AI algorithms, the research...

AI Hybrid Strategy Improves Mammogram In…

A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection...

New Training Year Starts at Siemens Heal…

In September, 197 school graduates will start their vocational training or dual studies in Germany at Siemens Healthineers. 117 apprentices and 80 dual students will begin their careers at Siemens...

Penn Developed AI Tools and Datasets Hel…

Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School...

Are You Eligible for a Clinical Trial? C…

A new study in the academic journal Machine Learning: Health discovers that ChatGPT can accelerate patient screening for clinical trials, showing promise in reducing delays and improving trial success rates. Researchers...

New AI Tool Addresses Accuracy and Fairn…

A team of researchers at the Icahn School of Medicine at Mount Sinai has developed a new method to identify and reduce biases in datasets used to train machine-learning algorithms...

Global Study Reveals How Patients View M…

How physicians feel about artificial intelligence (AI) in medicine has been studied many times. But what do patients think? A team led by researchers at the Technical University of Munich...